Royalty Pharma plc (RPRX)

NMS – Real vaqt narxi. Valyuta: USD

56.23

+1.54 (2.82%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

56.01

-0.22 (-0.39%)

Bozordan keyin: Jun 26, 2026, 7:57 PM EDT

11.06.2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

09.06.2026

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

09.06.2026

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.

05.06.2026

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

04.06.2026

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET.

19.05.2026

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

16.05.2026

Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead

Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma's positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers.

Videolar

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

01.08.2025

Negative

President Trump demands drugmakers slash prices within 60 days

Press-relizlar

06.05.2026

Royalty Pharma reports first quarter 2026 results

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma has delivered a strong start to 2026 across multiple dimensions.

21.04.2026

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients' lives. It will include a $1 million award distributed among one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field's most prominent awards.

17.04.2026

Royalty Pharma Declares Second Quarter 2026 Dividend

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share.

30.03.2026

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.

Royalty Pharma plc (RPRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Royalty Pharma plc (RPRX)

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead

Videolar

Press-relizlar

Royalty Pharma reports first quarter 2026 results

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Royalty Pharma Declares Second Quarter 2026 Dividend

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead

Videolar

Press-relizlar

Royalty Pharma reports first quarter 2026 results

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Royalty Pharma Declares Second Quarter 2026 Dividend

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Search stocks

Royalty Pharma plc (RPRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Royalty Pharma plc (RPRX)

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead

Videolar

Press-relizlar

Royalty Pharma reports first quarter 2026 results

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Royalty Pharma Declares Second Quarter 2026 Dividend

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead

Videolar

Press-relizlar

Royalty Pharma reports first quarter 2026 results

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Royalty Pharma Declares Second Quarter 2026 Dividend

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases